Regeneron Beneish M Score

REGN
 Stock
  

USD 624.83  11.51  1.81%   

This module uses fundamental data of Regeneron Pharmaceuticals to approximate the value of its Beneish M Score. Regeneron Pharmaceuticals M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Additionally, take a look at Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Altman Z Score analysis.
  
Regeneron Pharmaceuticals Debt Current is quite stable at the moment as compared to the past year. The company's current value of Debt Current is estimated at 123.59 Million. Long Term Debt to Equity is expected to rise to 0.11 this year, although the value of Total Debt will most likely fall to about 349.8 M. Regeneron Pharmaceuticals Accounts Payable Turnover is quite stable at the moment as compared to the past year. The company's current value of Accounts Payable Turnover is estimated at 34.63. Accrued Expenses Turnover is expected to rise to 11.88 this year, although the value of PPandE Turnover will most likely fall to 3.80.
At this time, it appears that Regeneron Pharmaceuticals is a possible manipulator. The earnings manipulation may begin if Regeneron Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Regeneron Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Regeneron Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-1.97
Beneish M Score - Possible Manipulator
Elasticity of Receivables1.0Focus
Asset Quality1.0Focus
Expense Coverage1.0Focus
Gross Margin Strengs1.16Focus
Accruals Factor1.0Focus
Depreciation Resistance1.0Focus
Net Sales Growth1.08Focus
Financial Leverage Condition0.98Focus

Regeneron Pharmaceuticals Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Regeneron Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues17.3 B16.1 B
Significantly Up
Increasing
Slightly volatile
Selling General and Administrative Expense1.1 B1.1 B
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations7.6 B7.1 B
Significantly Up
Increasing
Slightly volatile
Depreciation Amortization and Accretion101.7 M94.3 M
Significantly Up
Increasing
Slightly volatile
Total Assets27.4 B25.4 B
Significantly Up
Increasing
Slightly volatile
Investments1.3 B1.2 B
Significantly Up
Increasing
Slightly volatile
Investments Current488.9 M453.1 M
Significantly Up
Increasing
Slightly volatile
Investments Non Current839.2 M777.8 M
Significantly Up
Increasing
Slightly volatile
Property Plant and Equipment NetB1.9 B
Significantly Up
Increasing
Slightly volatile
Trade and Non Trade Receivables1.6 B1.5 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities7.2 B6.7 B
Significantly Up
Increasing
Slightly volatile
Current Assets15.1 B14 B
Significantly Up
Increasing
Slightly volatile
Assets Non Current3.7 B3.4 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities4.2 B3.9 B
Significantly Up
Increasing
Slightly volatile
Liabilities Non Current1.2 B1.2 B
Significantly Up
Increasing
Slightly volatile
Total Debt349.8 M431 M
Significantly Down
Increasing
Stable
Debt Current123.6 M114.5 M
Significantly Up
Increasing
Slightly volatile
Debt Non Current287.9 M316.4 M
Significantly Down
Decreasing
Stable
Operating Income9.7 B8.9 B
Significantly Up
Increasing
Slightly volatile
Gross Margin98.2384.8336
Fairly Up
Decreasing
Slightly volatile

Regeneron Pharmaceuticals Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Regeneron Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Regeneron Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Regeneron Pharmaceuticals' degree of accounting gimmicks and manipulations.

About Regeneron Pharmaceuticals Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

101.71 Million

Regeneron Pharmaceuticals Depreciation Amortization and Accretion is quite stable at the moment as compared to the past year. The company's current value of Depreciation Amortization and Accretion is estimated at 101.71 Million

Regeneron Pharmaceuticals Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Regeneron Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201720182019202020212022 (projected)
Revenues5.87 B6.71 B7.86 B8.5 B16.07 B17.34 B
Total Assets8.76 B11.73 B14.81 B17.16 B25.43 B27.44 B
Current Assets4.34 B6.45 B7.69 B9.78 B14.01 B15.12 B
Total Liabilities2.62 B2.98 B3.72 B6.14 B6.67 B7.19 B
Current Liabilities1.14 B1.44 B2.1 B2.7 B3.93 B4.24 B
Operating Income2.08 B2.53 B2.21 B3.58 B8.95 B9.65 B
Gross Margin93.2493.5390.0586.8284.8398.23

Regeneron Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regeneron Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regeneron Pharmaceuticals' managers, analysts, and investors.
Environment Score
Governance Score
Social Score

About Regeneron Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Regeneron Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people.

Regeneron Pharmaceuticals Investors Sentiment

The influence of Regeneron Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Regeneron. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Regeneron Pharmaceuticals' public news can be used to forecast risks associated with investment in Regeneron. The trend in average sentiment can be used to explain how an investor holding Regeneron can time the market purely based on public headlines and social activities around Regeneron Pharmaceuticals. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Regeneron Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Regeneron Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Regeneron Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Regeneron Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regeneron Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regeneron Pharmaceuticals' short interest history, or implied volatility extrapolated from Regeneron Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

Additionally, take a look at Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Altman Z Score analysis. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.73
Market Capitalization
70.5 B
Quarterly Revenue Growth YOY
-0.44
Return On Assets
0.18
Return On Equity
0.32
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.